CoChat

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Open access
Deken, Marcel A., Gadiot, Jules, Jordanova, Ekaterina S., Lacroix, Ruben, van Gool, Melissa, Kroon, Paula, Pineda, Cristina, Geukes Foppen, Marnix H., Scolyer, Richard, Song, Ji-Ying, Verbrugge, Inge, Hoeller, Christoph, Dummer, Reinhard, Haanen, John B. A. G., Long, Georgina V., Blank, Christian U. · 2016 · OncoImmunology
Cited by 153

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a proportion of patients long durable responses. In contrast, targeting the MAPK-pathway by selective BRAF and MEK inhibitors induces high response rates, but most patients relapse. Combining targeted therapy with immunotherapy is proposed to improve the long-term outcomes of patients. Preclinical data endorsing this hypothesis are accumulating. Inhibition of the PI3K-Akt-mTOR pathway may be a promising treatment option to overcome resistance to MAPK inhibition and for additional combination with immunotherapy.We therefore evaluated to which extent dual targeting of the MAPK and PI3K-Akt-mTOR pathways affects tumor immune infiltrates and whether it synergizes with PD-1 checkpoint blockade in a BRAFV600E/PTEN−/−-driven melanoma mouse model. Short-term dual BRAF + MEK inhibition enhanced tumor immune infiltration and improved tumor control when combined with PD-1 blockade in a CD8+ T cell dependent manner. Additional PI3K inhibition did not impair tumor control or immune cell infiltration and functionality. Analysis of on-treatment samples from melanoma patients treated with BRAF or BRAF + MEK inhibitors indicates that inhibitor-mediated T cell infiltration occurred in all patients early after treatment initiation but was less frequent found in on-treatment biopsies beyond day 15.Our findings provide a rationale for clinical testing of short-term BRAF + MEK inhibition in combination with immune checkpoint blockade, currently implemented at our institutes. Additional PI3K inhibition could be an option for BRAF + MEK inhibitor resistant patients that receive targeted therapy in combination with immune checkpoint blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2016.1238557

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 153

Metadata

Authors
Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M., Kroon, P., Pineda, C., Geukes Foppen, M. H., Scolyer, R., Song, J.-Y., Verbrugge, I., Hoeller, C., Dummer, R., Haanen, J. B. A. G., Long, G. V., & Blank, C. U.
Venue
OncoImmunology
Published
2016-10-14
Volume
5
Issue
12
Pages
e1238557
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2531876842
Cited by
153
References
19
FWCI
6.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. https://app.cochat.ai/papers/10.1080/2162402x.2016.1238557
The paper
Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M., Kroon, P., Pineda, C., Geukes Foppen, M. H., Scolyer, R., Song, J.-Y., Verbrugge, I., Hoeller, C., Dummer, R., Haanen, J. B. A. G., Long, G. V., & Blank, C. U. (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1238557

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.